JonesResearch initiated coverage of MindWalk (HYFT) with a Buy rating and $5 price target MindWalk offers an end-to-end ecosystem for drug discovery, but “what sets it apart” is its Bio-Native approach, built on a proprietary database of conserved “biological fingerprints, or HYFTs” linking sequence, structure, and function, the analyst tells investor. MindWalk’s capabilities span therapeutic areas as well as modalities, attracting partnerships across 19 of the top 20 pharmas in addition to chip maker AMD (AMD), the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYFT:
- MindWalk Holdings Reports March Insider Share Purchases and RSU Positions
- MindWalk Holdings Discloses March Insider Share Purchases in Voluntary U.S. Filing
- ImmunoPrecise Antibodies Earnings Call Highlights Growth
- MindWalk Holdings Delivers Q3 Revenue Surge and Secures First LensAI Platform Contract
- MindWalk Holdings Files Q3 2026 MD&A and Interim Financials